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Abstract
Objective: To investigate, in vitro, the regulatory effects of tumor-suppressing gene PTEN on
mTOR (mammalian target of rapamycin) signaling pathway, the effects of transfected PTEN and
rapamycin on the growth inhibition, and apoptosis induction for human leukemia cell line K562
cells.
Methods: K562 cells were transfected with recombined adenovirus-PTEN vector containing
green fluorescent protein (Ad-PTEN-GFP), followed by the treatment of the cells with or without
rapamycin. The proliferation inhibition rate and apoptotic rate of these transfected and/or
rapamycin treated K562 cells were measured by MTT assay and flow cytometry (FCM), the
expression levels of PTEN-, mTOR-, cyclinD1- and P27kip1- mRNA were measured by real-time
fluorescent relative-quantification reverse transcriptional PCR (FQ-PCR), the protein expression
levels of PTEN, Akt, p-Akt were detected by western blotting.
Results: The proliferation of K562 cells was inhibited by PTEN gene transfection with/without the
treatment of rapamycin. The expression levels of PTEN- and P27kip1- mRNA were up-regulated,
and the mTOR- and cyclinD1- mRNA were down-regulated in K562 cells after the cells transfected
with wild type PTEN gene and treated with rapamycin.
Conclusion: PTEN and rapamycin inhibited mTOR expression by acting as an upstream regulator
of mTOR. Low dose rapamycin in combination with over-expressed PTEN might have synergistic
effects on inhibiting the proliferation and promoting apoptosis of K562 cells.
Background
PTEN (phosphatase and tensin homology deleted on
chromosome ten) is a novel tumor suppressor gene, map-
ping to 10q23.3 and encoding a dual-specificity phos-
phatase with sequence similar to the cytoskeletal protein
tensin [1,2]. It was identified as a candidate tumor sup-
pressor gene based on the presence of gene deletion or
inactivating mutations in human brain, breast, and pros-
tate cancers and tumor cell lines [3-6]. PTEN protein can
be inactivated by post-transcriptional gene silencing, post-
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transcriptional modifications and GpG island methyla-
tion [3-8].
mTOR (mammalian target of rapamycin) gene locates in
the downstream of PI3K/Akt signal pathway, encoding a
serine/threonine protein kinase which is considered as an
oncoprotein. Studies showed that PI3K/Akt/mTOR and
MAPK and FAK signaling pathways and their downstream
partners were activated in leukemia, inducing the decon-
trolled proliferation and enhancing the invasiveness of
leukemia cells [9,10].
PTEN inhibits the activation of the above mentioned
pathways via its lipid phosphatase and protein phos-
phatase activities [8]. Rapamycin (RAPA), a triene mac-
rolide antibiotic, has anti-mTOR activity by binding
mTOR to interfere the interaction of mTOR with other tar-
get proteins in the signaling pathway. Targeting mTOR
signaling pathway can be a new strategy for the treatment
of leukemia [10-13].
Several studies showed that down-regulation of PTEN
mRNA expression and protein synthesis, and PI3K/Akt/
mTOR pathways were activated in the bcr/abl fusion pro-
tein positive K562 cells. However, the relationship
between the high expression of PTEN and the inactivation
of mTOR signal pathway and their effects on the prolifer-
ation of K562 cells were not clear. The present study was
designed to transfect K562 cells with recombined adeno-
virus-PTEN vector containing green fluorescent protein
(Ad-PTEN-GFP) or Ad-GFP vector followed by the treat-
ment of the cells with or without rapamycin. The regula-
tory mechanism of PTEN and rapamycin on mTOR
signaling pathway in K562 cells was then explored and the




Chemicals were purchased from Sigma-Aldrich and Qian-
gen Biotechnology (Qiangen, Beijing). Antibodies to
PTEN, Akt, p-AKT (serine 473), GAPDH were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Second-
ary antibodies for western blot analysis (horseradish per-
oxidase-conjugated anti-mouse Ig) were purchased from
Beijing Ding Guo biotechnology CO. LTD. Rapamycin
(RAPA) was from North China Pharmaceutical Group
Corporation. Other reagents were of analytical grade.
Cell culture
Human embryonic kidney cell line 293A cells were cul-
tured in the medium of HD DMEM, supplemented with
10% fetal bovine serum and used for adenovirus amplifi-
cation. K562 cells, a cell line established from a chronic
myelogenous leukemia patient in blast crisis, were cul-
tured in RPMI1640 supplemented with 10% fetal bovine
serum, glutamine (2%), penicillin (100 U/ml) and strep-
tomycin (100 μg/ml) at 37°C in a humidified atmosphere
with 5% CO2. Exponentially growing K562 cells were
seeded into flat-bottomed tissue-culture plates at the den-
sity of 5 × 105 cells/ml and cultured overnight
Cell transfection with Adenovirus Vectors
The first generation of recombinant adenovirus was gen-
erated by Jikai biological CO.LTD, Shanghai. The particle
titers of the adenoviral stocks were typically 1 × 10E9
plaque-forming units per milliliter (pfu/mL). Adenovirus
amplification was propagated in 293A cells for several
times to obtain high-titer stocks, as determined by the
plaque assay. Viral stocks of 1 × 10E9 pfu/mL were kept at
-80°C. Adenovirus vectors expressing the transgene PTEN,
containing green fluorescent protein (Ad-PTEN-GFP) or
empty vectors (Ad-Vector) were used to transfect the K562
cells. At the condition when multiplicity of infection
(MOI) was 200, K562 cells were co-cultured with Ad-
PTEN-GFP or Ad-GFP at 37°C, in a humidified atmos-
phere with 5% CO2, for 2 h. The transfection efficiency
was detected directly by FMC for the expression ratio of
green fluorescent protein.
Measurement of the effects of PTEN gene-transfection on 
K562 cells
From the first day to the seventh day after the transfection,
cell growth inhibition rate of the transfected K562 cells
from each group was measured by MTT method and FCM,
the mRNA expression levels of PTEN, mTOR, cyclinD1,
P27kip1 and BCR/ABL fusion gene in the transfected K562
cells were detected by FQ-PCR and the protein levels of
PTEN, Akt, p-Akt were measured by western blotting.
Measurement of growth inhibition effect of rapamycin on 
K562 cells
Raparamcin (RAPA) was dissolved in DMSO and then
added to the culture medium of the transfected K562 cells
or control K562 cells at the final concentrations of 0, 1, 5,
10, 20, 50 and 100 nmol/L. The effects of rapamycin,
together with PTEN transfection, on cell proliferation,
apoptosis and cell cycle were detected by MTT assay and
FCM when the K562 cells were treated with rapamycin for
12, 24, 48 or 72 hours. The mRNA expression levels of
PTEN, mTOR, cyclinD1, P27kip1 and BCR/ABL fusion gene
in the rapamycin reated and PTEN transfected K562 cells
were detected by FQ-PCR and the protein levels of PTEN,
Akt, p-Akt by western blotting.
Cell cycle distribution assay
For the cell cycle analysis, K562 cells (at least 1 × 105 cells)
from each group were collected at each culture-ending
point, washed and fixed with 70% ethanol, placed at 4°C
overnight. Then, the cells were treated with RNA enzymeJournal of Experimental & Clinical Cancer Research 2008, 27:87 http://www.jeccr.com/content/27/1/87
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for 30 minutes before the addition of propidium iodide
(PI), and then placed at 4°C for more than 15 minutes.
Finally, the cell cycle distribution (G0/G1 phase, S, G2/M)
and cell apoptosis rate was detected by FCM
Measurement of the target genes by FQ-PCR
K562 cells were collected from each group, washed with
PBS three times. Total RNA was extracted from the cells
according to the RNeasy Mini Protocol (Qiangen Biothch,
Beijing). Each 1 μg total RNA from each group of K562
cells was reversely transcribed in a 20 μL reaction mixture
which contained 0.5 μg oligo (dT)15 as primer by Super-
Script II reverse transcriptase (Promage). The resultant
cDNA was subjected to FQPCR. PCR was carried out in a
total 25 μl reaction system, with the SYBR Green I PCR
Reagent kit (Qiangen Biothech, Beijing) and a Lightcycler
fluoresencent quantitative amplification analyzer (Bio-
Rad, Hercules, CA). The reaction condition was 94°C for
5 min, 94°C 45s and 60°C 1 min, for 30 cycles. The fluo-
rescence signal of the first 3 to 15 cycles was settled as flu-
orescent background signal and the baseline was adjusted
accordingly. Relative quantification of gene expression
level was calculated by the following method: for each
reaction to amplify the target gene and β-actin gene, the Ct
value was determined. The ratio of of each target mRNA to
β-actin mRNA was calculated by the formula 2-ΔCt. The
specific primers' sequences for the target genes were
shown in Table 1.
Measurement of the target proteins by western blotting
Western blot analysis was performed for detecting the
expression level of specific protein in freshly washed K562
cells from each group. The protein concentrations of the
cell lysate were measured by coomassie brilliant blue kit
(Kang Chen Biotechnology, Beijing, China). Each 50 μg of
the cell lysate was loaded onto a 10% SDS-PAGE gel, and
run at 100 volts for 2 h. Cell proteins were transferred to
nitrocellulose membrane, blocked with 5% milk in TBS
(Tris-buffered saline with 0.1% Tween 20) for 1 h, then,
washed and incubated with the primary antibody for 1 h
at room temperature or overnight at 4°C. The blots were
washed and incubated with the horseradish peroxidase-
conjugated secondary antibody, and developed with a
chemiluminescent substrate, ECL Plus. Following devel-
opment of the primary antibodies, the bounded immu-
noglobulins were removed from the membranes by
washing twice, each time for 15 minutes at room temper-
ature in Restore Western blot Stripping Buffer. An autora-
diograph was obtained, and protein levels were measured
using a Fluors scanner and Quantity One software for
analysis (Bio-Rad).
Statistical analysis
tatistical analysis was done by Student's t-test and Spear-
man's test. Data was shown by mean ± SD of three inde-
pendent experiments. The results from each group were
compared with that of the corresponding control. P < 0.05
was considered as statistically significance.
Results
Anti-proliferation effect of PTEN transfection in K562 cells
Our preliminary experiment and several published papers
showed that K562 cells expressed PTEN mRNA and pro-
tein at very low levels [8]. Therefore, K562 cells were trans-
fected with Ad-PTEN-GFP or Ad-GFP in the present study.
After the transfection, the difference in cell growth inhibi-
tion rate between K562 cells from each group was not sta-
tistically significant in the first 3 days. The maximal
growth inhibition rate of 35.2% in Ad-PTEN-GFP trans-
fected K562 cells was detected at the fifth day and that was
statistically significant higher than that in Ad-GFP trans-
fected K562 cells and that in control K562 cells (P < 0.01
Fig 1).
PTEN transfection regulated the expression of specific 
genes and proteins in K562 cells
After transfection of Ad-PTEN-GFP to K562 cells, the
expression level of PTEN mRNA increased gradually,
Table 1: Primer sequence for FQPCR
Primers Sequence Product size Accession number from genebank
BCR/ABL F : 5'- GGAGCTGCAGATGCTGACCAAC-3' 200 bp AY789120
R : 5'- TCAGACCCTGAGGCTCAAAGT-3'
PTEN F : 5'-ATACCAGGACCAGAGGAAACC-3' 101 bp 000314
R : 5'-TTGTCATTATCCGCACGCTC-3'
mTOR F : 5'- GAGCCAGTGTTCCCTCCAT-3' 128 bp NM_152756
R : 5'- CAGTCAGCGGCCAGTCAT-3'
CyclinD1 F : 5'-CGATGCCAACCTCCTCAACGAC-3' 143 bp NM_053056
R : 5'-CCAGCATCCAGGTGGCGACG-3
P27kip1 F : 5'-ACGTGAGAGTGTCTAACGG-3' 138 bp NM_004064
R : 5'-AGTGCTTCTCCAAGTCCC-3'
β-actin F : 5'- CTGGCACCACACCTTCTACAAT -3' 382 bp NM_001101
R : 5'- AATGTCACGCACGATTTCCCGC -3'Journal of Experimental & Clinical Cancer Research 2008, 27:87 http://www.jeccr.com/content/27/1/87
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reached the top level on the third day and then decreased
gradually in the following three days, while the expression
level of mTOR mRNA decreased to the lowest level on the
third day and recovered gradually in the following three
days. However, the expression level of BCR/ABL fusion
gene did not change significantly (P > 0.05) (Fig 2). The
expression level of PTEN mRNA had negative correlation
with that of mTOR mRNA (r = -0.956, P < 0.05). The result
also showed that the expression level of PTEN protein
increased gradually after Ad-GFP-PTEN transfection, and
the top level was detected on the third day of the transfec-
tion. The expression level of p-Akt but not total Akt
decreased in PTEN transfected K562 cells, the lowest level
appeared on the third day (Fig 3).
PTEN transfection changed the cell cycle distribution in 
K562 cells
Cell cycle analysis by FCM showed that the percentage of
G2/M phase cells in Ad-PTEN-GFP transfected K562 cells
decreased, while the percentage of G0/G1 cells increased at
each tested time point. Cell cycle was arrested at the G0/G1
phase (Figure 4 and Table 2).
PTEN transfection and rapamycin treatment affected the 
growth and apoptosis of K562 cells
Previous studies showed that rapamycin have anti-inflam-
matory, anti-tumor and immunosuppressive activities.
Our results showed that the growth of K562 cells, which
were transfected with PTEN and treated with RAPA (10
nmol/L) for 72 h, was significantly inhibited by 37.4%.
This was significantly higher than that in K562 cells trans-
fected with Ad-GFP and treated with 10 nmol/L RAPA
(17.2%, P < 0.01) or that in K562 cells transfected with
PTEN but without RAPA treatment (7.5%, P < 0.01). The
apoptosis rate in K562 cells transfected with PTEN and
treated with 10 nmol/L RAPA for 3 days was 31.5%, sig-
nificantly higher than that in K562 cells transfected with
Ad-GFP and treated with 10 nmol/L RAPA (6.8%, P  <
0.01), or that in K562 cells transfected with Ad-PTEN-GFP
but without RAPA treatment (6.1%, P < 0.01) (Fig 5).
PTEN transfection and rapamycin treatment affected the 
expression of CyclinD1 and P27kip1 mRNA
CyclinD1 and P27kip1 mRNA and proteins were the key
factors in modulating cell cycle. The present study showed
that the expression level of CyclinD1 mRNA decreased in
K562 cells transfected with Ad-PTEN-GFP and treated
with 10 nmol/L RAPA for three days (0.121 ± 0.012),
which was significantly lower than that in Ad-PTEN-GFP
transfected K562 cells but without RAPA treatment (0.228
± 0.036, P < 0.01), or that in Ad-GFP transfected and 10
nmol/L RAPA treated K562 cells (0.675 ± 0.049). The
expression level of P27kip1 mRNA was negatively corre-
lated with that of CyclinD1 mRNA. P27kip1  mRNA
expressed at the top level (0.936 ± 0.061) in K562 cells
transfected with Ad-PTEN-GFP and treated with 10 nmol/
L RAPA for three days, which was significantly higher than
that in K562 cells transfected with Ad-PTEN-GFP but
Anti-proliferation effect of PTEN geng transfecion in K562 cells NC: Figure 1
Anti-proliferation effect of PTEN geng transfecion in K562 cells NC: controlled K562 cells; Ad-GFP: Ad-GFP tran-








 Journal of Experimental & Clinical Cancer Research 2008, 27:87 http://www.jeccr.com/content/27/1/87
Page 5 of 9
(page number not for citation purposes)
The expression levels of BCR/ABL, mTOR and PTEN mRNA in K562 cells transfected with PTEN gene (MOI = 200) Figure 2
The expression levels of BCR/ABL, mTOR and PTEN mRNA in K562 cells transfected with PTEN gene (MOI = 
200). *mTOR to right ordinate When the expression of PTEN mRNA increased, the expression of mTOR mRNA decreased 








                 
Akt, p-Akt and PTEN protein expression levels in K562 cells transfected with PTEN for different time point Figure 3
Akt, p-Akt and PTEN protein expression levels in K562 cells transfected with PTEN for different time point. 
The expression of p-Akt- protein in K562 cells decreased gradually following Ad-GFP-PTEN transfection, and the lowest level 
appeared on the third day of the transfection. PTEN protein increased gradually after Ad-GFP-PTEN transfection, and the top 
level was detected on the third day of the transfection. However, there was no obvious change in total Akt expression.
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without RAPA treatment (0.447 ± 0.032, P < 0.01), or that
in Ad-GFP transfected K562 cells (0.060 ± 0.007, P  <
0.01).
Discussion
PTEN gene is a novel tumor suppressor gene. PTEN pro-
tein has protein phosphatase and lipid phosphatase dual
activity, and has the activity against phosphatidylinositol
3, 4, 5- trisphosphate (PIP3), the major bioactive product
of PI3-kinase. The reduction of PIP3 level suppresses the
activation of Akt and allows apoptosis to occur.
Homozygous PTEN deletion is embryonic lethal in mice
and PTEN+/-  heterozygote mice may develop multiple
tumors or immune system abnormalities. The inactiva-
tion of PTEN in leukemia can be induced by gene silenc-
ing, DNA methylation, transcriptional regulation or post-
transcriptional modifications [14-16]. Our results showed
that PTEN mNRA and protein expressed at very low level
in K562 cells, a cell line established from a chronic myel-
ogenous leukemia patient in blast crisis. The over-expres-
sion of wild-type PTEN protein after PTEN gene
transfection showed an anti-proliferation and apoptosis
induction effect in the K562 cells in a time-dependent
manner, indicating that the wild type PTEN might have
anti-leukemia effect. Although previous studies showed
that a close correlation was found between the low expres-
sion of PTEN and the poor prognosis in some tumor
patients including hematological malignancies
[6,14,17,18] and the loss of PTEN gene disturbed the
maintenance of quiescent HSCs and promoted leukemo-
genesis in mice [19], the exact mechanism of hypo-expres-
sion of PTEN in human leukemogenesis was not clear.
The mammalian target of rapamycin (mTOR) is a serine/
threonine protein kinase, a downstream partner in PI3K/
Akt pathway, which regulates protein translation, cell
The cell cycle distribution of K562 cells transfected with Ad-PTEN-GFP or Ad-GFP and treated with or without 10 nM RAPA  detected by flow cytometry Figure 4
The cell cycle distribution of K562 cells transfected with Ad-PTEN-GFP or Ad-GFP and treated with or with-
out 10 nM RAPA detected by flow cytometry. A: transfected with Ad-GFP; B: transfected with Ad-GFP and treated with 
10 nmol/L RAPA; C: transfected with Ad-PTEN-GFP; D: transfected with Ad- PTEN-GFP and treated with 10 nmol/L RAPA. 
After treated with 10 nmol/L RAPA for three days, the apoptosis rate of K562 cells was 31.5% in Ad-PTEN-GFP group, which 
significantly higher than that of 6.8% in Ad-GFP group_P < 0.01).
 
Table 2: The comparison of Apoptosis rate and cell cycle change 
in K562 cells transfected with or without PTEN gene for 
different time.(%)
Group Untransfected Ad-GFP Ad-PTEN-GFP
Apoptosis G2/M Apoptosis G2/M Apoptosis G2/M
2d 0.2 30.2 0.8 29.3 1.5 28.1
5d 0.5 30.8 2.8 26.9 22.4 23.3
7d 1.1 29.7 4.1 32.9 30 13.6Journal of Experimental & Clinical Cancer Research 2008, 27:87 http://www.jeccr.com/content/27/1/87
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growth and apoptosis [20]. Abnormalities in the PI3K/
AKT/mTOR signal pathway occurs in many solid or hema-
tological malignancies. The present study also showed
that mTOR mRNA and p-Akt protein expressed at high
levels in K562 cells. After the cells were transfected with
PTEN gene and treated with rapamycin, the expression
levels of mTOR mRNA and p-Akt protein decreased
accordingly. This result demonstrated that deregulated
PI3K/AKT/mTOR signal pathway might contribute to the
development of leukemia, and could be considered as a
candidate target for the treatment of leukemia.
Rapamycin can stabilize the inhibitors of PI3K/AKT/
mTOR signaling pathway and down-regulate the activity
of mTOR. Studies showed that inhibiting mTOR with
rapamycin decreased the phosphorylation of proteins in
mTOR signaling pathway, induced cell cycle arrest at G0/
G1 phase and distinctly rescued the differentiation of nor-
mal hematolpoietic stem cells (HSCs) and depleted leuke-
mic stem cells. The regulation of HSCs and leukemic cells
might be governed by cell-context-dependent, PTEN-
mediated inhibition of mTOR [21]. The cell cycle arrest
associated with the down-regulation of cyclinD1 and up-
The cell growth inhibition effect of rapamycin combined with PTEN transfection Figure 5
The cell growth inhibition effect of rapamycin combined with PTEN transfection.
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regulation of the cdk inhibitors p27kip1 and p21cip1 [9-11].
Therefore, inhibition of mTOR function represents a
potential therapeutic strategy [10-13]. Our results showed
that in the PTEN gene transfected K562 cells, over-
expressed PTEN gene combined with the treatment of
rapamycin significantly promoted the expression of
P27kip1 gene but inhibited the expression of the CyclinD1.
Meanwhile, the percentage of cells in S and G2/M phase
decreased and the cells in G0/G1 phase increased in the
PTEN gene transfected K562 cells. These results suggested
that PTEN gene and protein might inhibit the expression
and the function of cyclins and cyclins-CDK but promote
expression of P27kip1  via down-regulating p-Akt and
mTOR expression.
Several published papers showed that rapamycin played
key role in inhibiting tumor proliferation by targeting
mTOR and had synergistic anti-tumors effects with some
chemotherapeutic drugs such as arsenic trioxide in several
kinds of tumors [22]. The present study showed that PTEN
gene transfection, together with the treatment of low con-
centration of rapamycin, had a higher growth inhibition
effect and apoptosis induction effect in K562 cell, accom-
panied with the increased expression of PTEN mRNA and
protein but decreased expression of mTOR, suggesting
that rapamycin and PTEN might have synergic effect on
inhibiting proliferation, promoting apoptosis and cell
cycle arrest of leukemia cells via inhibiting the activity of
PI3K/Akt/mTOR pathway. These results might provide a
theoretical basis for the treatment of CML with new mol-
ecule targeting regimens such as PTEN transfection and
the use of rapamycin.
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